Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.05 (-5.24%)
Close on Nov 13, 2026Market cap $280.72MP/E –Yield –
Ocugen total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Ocugen's total debt was $1.78M at Sep 30, 2026. For fiscal 2025 it was $28.79M, up 0.4% from the year before. The highest annual figure on record is $28.79M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.79M | +0.4% |
| FY2024 | Dec 31, 2024 | $28.67M | +924.0% |
| FY2023 | Dec 31, 2023 | $2.80M | +22.3% |
| FY2022 | Dec 31, 2022 | $2.29M | +33.7% |
| FY2021 | Dec 31, 2021 | $1.71M | -16.8% |
| FY2020 | Dec 31, 2020 | $2.06M | +91.9% |
| FY2019 | Dec 31, 2019 | $1.07M | -87.4% |
| FY2018 | Dec 31, 2018 | $8.50M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.78M | -93.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.75M | -93.8% |
| Q1 FY2026 | Mar 31, 2026 | $29.19M | +5.5% |
| Q4 FY2025 | Dec 31, 2025 | $28.79M | +0.4% |
| Q3 FY2025 | Sep 30, 2025 | $28.40M | +883.7% |
| Q2 FY2025 | Jun 30, 2025 | $28.03M | +880.6% |
| Q1 FY2025 | Mar 31, 2025 | $27.67M | +878.0% |
| Q4 FY2024 | Dec 31, 2024 | $28.67M | +924.0% |
| Q3 FY2024 | Sep 30, 2024 | $2.89M | +4.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.86M | +4.4% |
| Q1 FY2024 | Mar 31, 2024 | $2.83M | +22.3% |
| Q4 FY2023 | Dec 31, 2023 | $2.80M | +22.3% |
| Q3 FY2023 | Sep 30, 2023 | $2.77M | +22.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.74M | +56.5% |
| Q1 FY2023 | Mar 31, 2023 | $2.31M | +33.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.29M | +33.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.27M | +33.8% |
| Q2 FY2022 | Jun 30, 2022 | $1.75M | +4.5% |
| Q1 FY2022 | Mar 31, 2022 | $1.73M | -16.6% |
| Q4 FY2021 | Dec 31, 2021 | $1.71M | -16.8% |
| Q3 FY2021 | Sep 30, 2021 | $1.69M | -46.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.67M | -72.5% |
| Q1 FY2021 | Mar 31, 2021 | $2.08M | +31.3% |
| Q4 FY2020 | Dec 31, 2020 | $2.06M | +91.9% |
| Q3 FY2020 | Sep 30, 2020 | $3.16M | +198.2% |
| Q2 FY2020 | Jun 30, 2020 | $6.09M | -28.4% |
| Q1 FY2020 | Mar 31, 2020 | $1.58M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.07M | – |
| Q3 FY2019 | Sep 30, 2019 | $1.06M | – |
| Q4 FY2018 | Dec 31, 2018 | $8.50M | – |
See a number that looks wrong?